BUENA, N.J., July 24, 2014 /PRNewswire/ -- IGI Laboratories,
Inc. (NYSE MKT: IG), a New Jersey
based specialty generic pharmaceutical company, today announced it
has accepted Damian Finio's
resignation from its Board of Directors. Mr. Finio has
accepted a senior level finance position at a pharmaceutical
company, and under the terms of his acceptance of his new position,
Mr. Finio will be unable to continue in his role as Director for
IGI Laboratories, Inc. The effective date of his resignation
will be August 11, 2014. The
Company has begun a search to replace Mr. Finio on its Board of
Directors.
About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic drug development and
manufacturing company. Our mission is to be a leading player in the
specialty generic prescription drug market.
IGI Laboratories, Inc. "Safe Harbor" Statement under the Private
Securities Litigation Reform Act of 1995. This press release
includes certain "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, plans,
objectives, expectations and intentions, and other statements
contained in this press release that are not historical facts and
statements identified by words such as " will," "believe",
"target", "estimated," "continue" or words of similar meaning.
These statements are based on our current beliefs or expectations
and are inherently subject to various risks and uncertainties,
including those set forth under the caption "Risk Factors" in IGI
Laboratories, Inc.'s most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q and other reports we file with the
Securities and Exchange Commission. Actual results may differ
materially from these expectations. Factors that could cause actual
results to differ materially from these expectations include, but
are not limited to: our inability to meet current or future
regulatory requirements in connection with existing or future
ANDAs; our inability to achieve profitability; our failure to
obtain FDA approvals as anticipated; our inability to execute and
implement our business plan and strategy; the potential lack of
market acceptance of our products; our inability to protect our
intellectual property rights; changes in global political,
economic, business, competitive, market and regulatory factors; and
our inability to complete successfully future product acquisitions.
IGI Laboratories, Inc. does not undertake any obligation to update
any forward-looking statements contained in this document as a
result of new information, future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20130827/MM70487LOGO
SOURCE IGI Laboratories, Inc.